Background: Because continued cigarette smoking after a cancer diagnosis is associated with detrimental outcomes, supporting cancer patients with smoking cessation is imperative. We evaluated the effect of the Smoking Cessation Program at the London Regional Cancer Program (lrcp) over a 2-year period. Methods: The Smoking Cessation Program at the lrcp began in March 2014. New patients are screened for tobacco use. Tobacco users are counselled about the benefits of cessation and are offered referral to the program. If a patient accepts, a smoking cessation champion offers additional counselling. Follow-up is provided by interactive voice response (ivr) telephone system. Accrual data were collected monthly from January 2015 to December 2016 and were evaluated. Results: During 2015-2016, 10,341 patients were screened for tobacco use, and 18% identified themselves as current or recent tobacco users. In 2015, 84% of tobacco users were offered referral, but only 13% accepted, and 3% enrolled in ivr follow-up. At the lrcp in 2016, 77% of tobacco users were offered referral to the program, but only 9% of smokers accepted, and only 2% enrolled in ivr follow-up. Conclusions: The Smoking Cessation Program at the lrcp has had modest success, because multiple factors influence a patient's success with cessation. Limitations of the program include challenges in referral and counselling, limited access to nicotine replacement therapy (nrt), and minimal follow-up. To mitigate some of those challenges, a pilot project was launched in January 2017 in which patients receive free nrt and referral to the local health unit.
Background: Because continued cigarette smoking after a cancer diagnosis is associated with detrimental outcomes, supporting cancerpatients with smoking cessation is imperative. We evaluated the effect of the Smoking Cessation Program at the London Regional Cancer Program (lrcp) over a 2-year period. Methods: The Smoking Cessation Program at the lrcp began in March 2014. New patients are screened for tobacco use. Tobacco users are counselled about the benefits of cessation and are offered referral to the program. If a patient accepts, a smoking cessation champion offers additional counselling. Follow-up is provided by interactive voice response (ivr) telephone system. Accrual data were collected monthly from January 2015 to December 2016 and were evaluated. Results: During 2015-2016, 10,341 patients were screened for tobacco use, and 18% identified themselves as current or recent tobacco users. In 2015, 84% of tobacco users were offered referral, but only 13% accepted, and 3% enrolled in ivr follow-up. At the lrcp in 2016, 77% of tobacco users were offered referral to the program, but only 9% of smokers accepted, and only 2% enrolled in ivr follow-up. Conclusions: The Smoking Cessation Program at the lrcp has had modest success, because multiple factors influence a patient's success with cessation. Limitations of the program include challenges in referral and counselling, limited access to nicotine replacement therapy (nrt), and minimal follow-up. To mitigate some of those challenges, a pilot project was launched in January 2017 in which patients receive free nrt and referral to the local health unit.
Authors: Graham W Warren; Shiva Dibaj; Alan Hutson; K Michael Cummings; Carolyn Dresler; James R Marshall Journal: J Thorac Oncol Date: 2015-11 Impact factor: 15.609
Authors: J Lee Westmaas; Christina C Newton; Victoria L Stevens; W Dana Flanders; Susan M Gapstur; Eric J Jacobs Journal: J Clin Oncol Date: 2015-04-20 Impact factor: 44.544
Authors: Robert A Schnoll; Elisa Martinez; Kristina L Tatum; Dorothy M Weber; Natalie Kuzla; Marcella Glass; John A Ridge; Corey Langer; Curtis Miyamoto; E Paul Wileyto; Frank Leone Journal: Cancer Causes Control Date: 2010-01-20 Impact factor: 2.506
Authors: Aidin Kashigar; Steven Habbous; Lawson Eng; Brendan Irish; Eric Bissada; Jonathan Irish; Dale Brown; Ralph Gilbert; Patrick Gullane; Wei Xu; Shao-Hui Huang; Ian Witterick; Jeremy Freeman; Brian O'Sullivan; John Waldron; Geoffrey Liu; David Goldstein Journal: Cancer Date: 2013-06-13 Impact factor: 6.860
Authors: Lorna Sampson; Janet Papadakos; Victoria Milne; Lisa W Le; Geoffrey Liu; Nazek Abdelmutti; Robin Milne; David P Goldstein; Lawson Eng; Meredith Giuliani Journal: J Cancer Educ Date: 2018-02 Impact factor: 2.037
Authors: Kristen McCarter; Úrsula Martínez; Ben Britton; Amanda Baker; Billie Bonevski; Gregory Carter; Alison Beck; Chris Wratten; Ashleigh Guillaumier; Sean A Halpin; Luke Wolfenden Journal: BMJ Open Date: 2016-09-20 Impact factor: 2.692
Authors: Astrid Lahousse; Eva Roose; Laurence Leysen; Sevilay Tümkaya Yilmaz; Kenza Mostaqim; Felipe Reis; Emma Rheel; David Beckwée; Jo Nijs Journal: J Clin Med Date: 2021-12-30 Impact factor: 4.241
Authors: Jessica L Burris; Tia N Borger; Brent J Shelton; Audrey K Darville; Jamie L Studts; Joseph Valentino; Courtney Blair; D Bront Davis; Joan Scales Journal: JCO Oncol Pract Date: 2021-06-29
Authors: Stacey A Santi; Michael S C Conlon; Margaret L Meigs; Stacey M Davidson; Kyle Mispel-Beyer; Deborah P Saunders Journal: Curr Oncol Date: 2022-03-02 Impact factor: 3.677